单位：[1]Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China[2]National Center for Respiratory Medicine, Beijing, China[3]Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China[4]National Clinical Research Center for Respiratory Diseases, Beijing, China, [5]WHO Collaborating Centre for Tobacco Cessation and Respiratory Diseases Prevention, Beijing, China[6]Harbin Medical University, Harbin, China[7]Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[8]School of Medicine, Tsinghua University, Beijing, China[9]Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China,[10]Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Idiopathic pulmonary fibrosis (IPF) is an interstitial disease of unknown etiology characterized by progressive pulmonary fibrosis. Pirfenidone and nintedanib are the only drugs that can prolong the time to disease progression, slow down the decline in lung function, and prolong survival. However, they do not offer a cure and are associated with tolerability issues. The pluripotency of mesenchymal stem cells (MSCs) and their ability to regulate immunity, inhibit inflammation, and promote epithelial tissue repair highlight the promise of MSC therapy for treating interstitial lung disease. However, optimal protocols are lacking for multi-parameter selection in MSC therapy. This review summarizes preclinical studies on MSC transplantation for the treatment of interstitial lung disease and clinical studies with known results. An analysis of relevant factors for the optimization of treatment plans is presented, including MSCs with different sources, administration routes and timing, dosages, frequencies, and pretreatments with MSCs. This review proposes an optimized plan for guiding the design of future clinical research to identify therapeutic options for this complex disease.
基金：
Chinese Academy of Medical Sciences, Science and Technology Innovation in Medicine and Health Project (Major Collaborative Innovation Project) [2018-I2M-1-0001]; Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences [2019PT320021]
第一作者单位：[1]Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China[2]National Center for Respiratory Medicine, Beijing, China[3]Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China[4]National Clinical Research Center for Respiratory Diseases, Beijing, China, [5]WHO Collaborating Centre for Tobacco Cessation and Respiratory Diseases Prevention, Beijing, China[6]Harbin Medical University, Harbin, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China[2]National Center for Respiratory Medicine, Beijing, China[3]Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China[4]National Clinical Research Center for Respiratory Diseases, Beijing, China, [5]WHO Collaborating Centre for Tobacco Cessation and Respiratory Diseases Prevention, Beijing, China
推荐引用方式(GB/T 7714)：
Shengnan Yang,Peipei Liu,Yale Jiang,et al.Therapeutic Applications of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis[J].FRONTIERS in CELL and DEVELOPMENTAL BIOLOGY.2021,9:doi:10.3389/fcell.2021.639657.
APA：
Shengnan Yang,Peipei Liu,Yale Jiang,Zai Wang,Huaping Dai&Chen Wang.(2021).Therapeutic Applications of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis.FRONTIERS in CELL and DEVELOPMENTAL BIOLOGY,9,
MLA：
Shengnan Yang,et al."Therapeutic Applications of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis".FRONTIERS in CELL and DEVELOPMENTAL BIOLOGY 9.(2021)
：